What Does the Research Say About Cannabis, Aging, and Longevity?

Eleven preclinical studies showed promising results for cannabinoids in aging, including improved lifespan, cognitive function, reduced inflammation, better sleep, and enhanced social interaction. Low-dose THC appeared beneficial while higher doses showed drawbacks. Seven human studies suggested potential therapeutic applications but were insufficient for comprehensive conclusions.

PRISMA-guided systematic review of 18 studies (11 preclinical using C. elegans, rodents, zebrafish, mice; 7 human studies in populations aged 50+) investigating the direct impact of cannabinoids on aging and longevity.

With global populations aging rapidly, identifying interventions that support healthy aging is a major research priority. This review is among the first to systematically compile what is known about how cannabinoids interact with the aging process through the endocannabinoid system.

The endocannabinoid system changes with age, and there is growing interest in whether modulating it with cannabinoids could slow age-related decline. This review highlights the gap between encouraging preclinical results and the limited human evidence, a common challenge in cannabinoid research.

Only 18 studies met inclusion criteria, reflecting how little direct research exists on this topic. Most evidence comes from animal models that may not translate to humans. The seven human studies were heterogeneous in design and endpoints. Publication bias may favor positive results.